| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/03/2009 | US7498360 Adminisering prostaglandin into ear |
| 03/03/2009 | US7498358 Human ADAM-10 inhibitors |
| 03/03/2009 | US7498352 TGF-β superfamily production/secretion promoter |
| 03/03/2009 | US7498340 Topoisomerase I inhibitors; improved stability, water solubility, toxicity; anticancer agents; camptothecins bearing an oxime group in position 7; 7-tert-butoxyiminomethyl-20-O-(4-trimethyl-ammonium-3-hydroxy)butanoyl-camptothecin bromide; glioma |
| 03/03/2009 | US7498335 Method of producing an antiangiogenic or vascular permeability reducing effect |
| 03/03/2009 | US7498334 Pyrrolopyrimidines as phosphodiesterase VII inhibitors |
| 03/03/2009 | US7498330 4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds |
| 03/03/2009 | US7498328 Derivatives of sulphonamides, their preparation and use as medicaments |
| 03/03/2009 | US7498324 Substituted lactams as inhibitors of Aβ protein production |
| 03/03/2009 | US7498323 Spiro-piperidine compounds and medicinal use thereof |
| 03/03/2009 | US7498321 17β-carbothioate 17α-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 03/03/2009 | US7498308 The analogs are resistant to diaminopeptidase IV degradation and bind zinc; are active over an extended time in vivo |
| 03/03/2009 | US7498302 Analogues of rachelmycin and the duocarmycins that are potent cytotoxins containing a benzodipyrrole or naphthopyrrole ring; anticancer agents |
| 03/03/2009 | US7498299 Optionally containing a recognition sequence for affinity purification; treating fibrotic liver disorders |
| 03/03/2009 | US7498157 Polypeptide crystal having a polyhistidine tag added to the C-terminal end; effectors; drug screening for enzyme inhibitors; multiple sclerosis, diabetes, Grave's disease, rheumatic arthritis, AIDS, cancer, immunomodulators |
| 03/03/2009 | US7498147 Modulating the activity of one or more elements in the complement/lipid pathway |
| 03/03/2009 | US7498143 Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 03/03/2009 | US7498127 Drug screening for cytostatic agent intracellular signaling inhibitor such as antitumor agents, antirheumatic agents; cardiovascular disorders; producing within a cell a fragment of heparin binding-epidermal growth factor (HB-EGF); determination of nuclear export of PLZF protein |
| 03/03/2009 | US7498038 Chitin microparticles and their medical uses |
| 03/03/2009 | US7498034 Imaging, diagnosis and treatment of disease |
| 03/03/2009 | US7498031 Treating sensorineural hearing loss or a vestibular disorder by administering an a PM-1antibody or an MR16-1 antibody; Meniere's disease, drug-induced inner ear disorders, viral inner ear disorders, purulent inner ear disorders, temporal bone fracture or acoustic nerve tumor |
| 03/03/2009 | CA2314453C Processes of making north american ginseng fractions, products containing them, and use as immunomodulators |
| 03/03/2009 | CA2258165C N-[4-(heteroarylmethyl)phenyl]-heteroarylamines |
| 03/03/2009 | CA2237368C 5'-deoxy-cytidine derivatives |
| 02/26/2009 | WO2009026456A2 Poxvirus methods and compositions |
| 02/26/2009 | WO2009025398A1 Decellularizing solution, method of preparing decellularized tissue, graft and culture member |
| 02/26/2009 | WO2009025358A1 Heterocyclic compound and use thereof |
| 02/26/2009 | WO2009025300A1 Peptide capable of binding to immunoglobulin |
| 02/26/2009 | WO2009025265A1 Piperazine derivative |
| 02/26/2009 | WO2009025239A1 Novel preparation for external use |
| 02/26/2009 | WO2009025196A1 Foxm1 peptide and medicinal agent comprising the same |
| 02/26/2009 | WO2009025149A1 Adnf receptor |
| 02/26/2009 | WO2009025117A1 Cdca1 peptide and pharmaceutical agent comprising the same |
| 02/26/2009 | WO2009025116A1 Cdh3 peptide and medicinal agent comprising the same |
| 02/26/2009 | WO2009024977A2 Saccharide-containing protein conjugates and uses thereof |
| 02/26/2009 | WO2008073961A3 Compounds and methods for modulating the silencing of a polynucleotide of interest |
| 02/26/2009 | WO2008036117A3 Nanogel contrast agents for optical molecular imaging |
| 02/26/2009 | US20090054530 Methods and Compositions that Enhance Bioavailability of Coenzyme-Q10 |
| 02/26/2009 | US20090054528 Bridged polycyclic compound based compositions for coating oral surfaces in pets |
| 02/26/2009 | US20090054519 Derivatives of monosaccharides as 5-lipoxygenase inhibitors |
| 02/26/2009 | US20090054495 4-Chloro-2-phenylsulfanyl-phenyl)-4-isopropoxy-benzenesulfonamide; inflammatory bowl disease such as Crohn's disease or Colitis |
| 02/26/2009 | US20090054486 Polymorphic form xvi of fexofenadine hydrochloride |
| 02/26/2009 | US20090054480 Novel quinuclidine carbamate derivatives and medicinal compositions containing the same |
| 02/26/2009 | US20090054467 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases |
| 02/26/2009 | US20090054459 Substituted indoles |
| 02/26/2009 | US20090054446 Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists |
| 02/26/2009 | US20090054436 anticarcinogenic compounds; ; N-(4-(2-Aminopyridin-4-yloxy)-3-fluorophenyl)-2-bromoisonicotinamide, trifluoroacetic acid salt; inhibit the protein tyrosine kinase activity of growth factor receptors like Hepatocyte growth factor |
| 02/26/2009 | US20090054424 Optically active pyridine derivative and a medicament containing the same |
| 02/26/2009 | US20090054402 7-substituted indole mcl-1 inhibitors |
| 02/26/2009 | US20090054397 Pyrazole compounds and pharmaceutical compositions comprising the compound |
| 02/26/2009 | US20090054385 Solid inhalation formulations of dehydroepiandrosterone derivatives |
| 02/26/2009 | US20090054339 Novel cellular factor-containing solution compositions |
| 02/26/2009 | US20090054331 High temperature stable peptide formulation |
| 02/26/2009 | US20090054320 Vesiculins |
| 02/26/2009 | US20090054302 Methods and Preparations For Curing Clinically Ill Patients |
| 02/26/2009 | US20090053805 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 02/26/2009 | US20090053802 Multipotent stem cells from peripheral tissues and uses thereof |
| 02/26/2009 | US20090053342 Preparation of microbial oil |
| 02/26/2009 | US20090053307 Immediate-release therapeutic systems for improved oral absorption of 7-[(e)]-t-buty-loxyminomethyl] camptothecin |
| 02/26/2009 | US20090053298 constitutive active/androstane receptor (CAR); antisense agents; drug screening; hepatocytes |
| 02/26/2009 | US20090053295 Regulatable fusion promoters |
| 02/26/2009 | US20090053256 inducing an immune response to a poxvirus in a mammal by administering a composition comprising a nucleic acid molecule comprising nucleotide sequence encoding a variola F8 polypeptide, wherein nucleotide sequence is codon optimized for expression in both a mammalian cell and a bacterial cell |
| 02/26/2009 | US20090053252 Bimer or an oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins |
| 02/26/2009 | US20090053234 Methods of Preventing or Treating Inflammatory or Autoimmune Disorders by Administering Integrin ALPHAVBETA3 Antogonists in Combination with other Prophylactic or Therapeutic Agents |
| 02/26/2009 | US20090053223 Expression-enhanced polypeptides |
| 02/26/2009 | US20090053198 Cytokine Induction of Selectin Ligands on Cells |
| 02/26/2009 | US20090053173 Stabilization of such as human interleukin 11; reduced toxicity; cost effective; shelf life; SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma; between a human serum albumin and an Interferon |
| 02/26/2009 | US20090053143 Liquid inhalation formulations of dehydroepiandrosterone derivatives |
| 02/26/2009 | DE112007001030T5 Amyloid-ß-Fibrillogenese-inhibierendes Peptid Amyloid-beta fibrillogenesis-inhibiting peptide |
| 02/26/2009 | CA2696793A1 Novel preparation for external use |
| 02/26/2009 | CA2696701A1 Cdca1 peptide and pharmaceutical agent comprising the same |
| 02/26/2009 | CA2696699A1 Saccharide-containing protein conjugates and uses thereof |
| 02/26/2009 | CA2696597A1 Foxm1 peptide and medicinal agent comprising the same |
| 02/26/2009 | CA2696591A1 Cdh3 peptide and medicinal agent comprising the same |
| 02/25/2009 | EP2028278A1 RNA sequence-specific mediators of RNA interference |
| 02/25/2009 | EP2028191A1 Peptides and compounds that bind to a receptor |
| 02/25/2009 | EP2028187A1 Human and mouse targeting peptides identified by phage display |
| 02/25/2009 | EP2027873A1 One dose vaccination with mycoplasma hyopneumoniae |
| 02/25/2009 | EP2027872A1 Neurotoxic component of a botulinum toxin for treating a facial disease |
| 02/25/2009 | EP2027862A1 Composition for enhancing immune function |
| 02/25/2009 | EP2027855A1 Use of gestagens in combination with (6S)5-methyl tetrahydro folate for endometriosis therapy with simultaneous reduction of the side effects of therapy and reduction in the risk of congenital deformities for with the onset of pregnancy |
| 02/25/2009 | EP2027853A2 Kinase inhibitors for treating cancers |
| 02/25/2009 | EP2026801A2 Method of treatment of hereditary hemochromatosis |
| 02/25/2009 | EP2026778A2 Use of a rar antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects |
| 02/25/2009 | EP1878732B1 HIGHLY SELECTIVE Rho-KINASE INHIBITOR |
| 02/25/2009 | EP1778205B1 Hydrating composition |
| 02/25/2009 | EP1506188B1 Process for the preparation of a hydrate of an anthranilic acid derivative |
| 02/25/2009 | EP1381361B1 Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
| 02/25/2009 | EP1365651A4 Composition and methods for modulation of vascular structure and/or function |
| 02/25/2009 | EP1254106B1 Calcilytic compounds |
| 02/25/2009 | EP1247532B1 Composition promoting lacrimal secretion |
| 02/25/2009 | EP1143965B1 Carbocyclic potassium channel inhibitors |
| 02/25/2009 | EP1075277B1 Methods for detecting and inhibiting angiogenesis |
| 02/25/2009 | EP1027056B1 Alpha-ketoamide multicatalytic protease inhibitors |
| 02/25/2009 | EP0852587B1 Synthetic peptides that inhibit il-6 activity |
| 02/25/2009 | CN101374519A Modulators of muscarinic receptors |
| 02/25/2009 | CN101371897A Pollen medicine for regulating qi |
| 02/25/2009 | CN101371894A Pollen medicine for lack of appetite |
| 02/25/2009 | CN101371852A Method for preventing and treating leukoderma of prawn |
| 02/25/2009 | CN101371828A Hypocrellin liposome preparation and preparation method thereof |